ASH 2022 | Journaal benigne hematologie

In dit speciale journaal bespreekt prof. dr. Bart Biemond zijn selectie van het belangrijkste ASH-nieuws op het gebied van immuun trombocytopenie, trombotische microangiopathie en sikkelcelziekte. 

De volgende abstracts komen in dit journaal ter sprake: 

SCD 

• Interim Analysis of a Phase 2 Trial to Assess the Efficacy and Safety of Crizanlizumab in Sickle Cell Disease Patients with Priapism (SPARTAN)

• Hormonal Contraceptive Use and Association with Thromboembolism in Women with Sickle Cell Disease 

• Sickle Cell Disease Patients Mount Adequate Humoral but Reduced Cellular Responses to COVID-19 Vaccination

• Real-World Effectiveness of Voxelotor for the Treatment of Sickle Cell Disease: Group and Pediatric Subgroup Analyses of Effects on Transfusions, Vaso-Occlusive Crises, and Hospitalizations

• Effect of Voxelotor on Cerebral Perfusion and Cerebral Oxygen Metabolism in Adult Patients with Sickle Cell Disease; Preliminary Results of the Coverage Study

ITP & TTP 

• Efficacy and Safety of Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: Results of a Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV)

• Cognitive impairment in patients with Immune Thrombocytopenia

• The Role of ADAMTS13 Activity Levels on Disease Exacerbation or Relapse in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura: Post Hoc Analysis of the Phase 3 HERCULES and Post-HERCULES Studies

• Silent Cerebral Infarction during Immune TTP Remission – Prevalence, Predictors and Impact on Cognition

PNH

• Oral Monotherapy with Iptacopan, a Proximal Complement Inhibitor of Factor B, Has Superior Efficacy to Intravenous Terminal Complement Inhibition with Standard of Care Eculizumab or Ravulizumab and Favorable Safety in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia: Results from the Randomized, Active-Comparator-Controlled, Open-Label, Multicenter, Phase III Apply-PNH Study

Bekijk hier het volledige overzicht van onze ASH 2022 journaals en interviews.